Engot-Ov16/Nova: a Phase 3 Randomized Double-Blind Trial of Maintenance with Parp-Inhibitor Niraparib Versus Placebo in Patients with Platinum-Sensitive Ovarian Cancer

Journal article

Open access

Peer reviewed

M.R. Mirza, B.J. Monk, J.A. Ledermann, A.M. Oza, J.M. Del Campo, J.S. Berek, S. Mahner, R.M. Wenham, I.B. Vergote, M. Fabbro, …

Annals of oncology, Vol.25, p.iv325

09/2014

Files and links (1)

url

https://doi.org/10.1093/annonc/mdu338.65View

Published (Version of record) Open

4 Record Views

Title: Engot-Ov16/Nova: a Phase 3 Randomized Double-Blind Trial of Maintenance with Parp-Inhibitor Niraparib Versus Placebo in Patients with Platinum-Sensitive Ovarian Cancer
Creators: M.R. Mirza - Rigshospitalet
B.J. Monk - Dignity Health
J.A. Ledermann - University College London
A.M. Oza - Princess Margaret Cancer Centre
J.M. Del Campo - Spanish Ovarian Cancer Research Group
J.S. Berek - Gynecology, Stanford Cancer Institute, Stanford, CA, USA
S. Mahner - University Medical Center Hamburg-Eppendorf
R.M. Wenham - Moffitt Cancer Center
I.B. Vergote - KU Leuven
M. Fabbro - CEA Valduc
C. Marth - University Hospital Innsbruck
A. Dørum - Norwegian Cancer Society
D. Lorusso - Mylan
D. Katsaros - Ospedale Sant'Anna
I. Bruchim - Gynecology, ISGO, Tel Aviv, ISRAEL
S. Malander - Lund University
J. Herrstedt - Odense University Hospital
S. Agarwal - Tesaro
R.E. Martell
U. Matulonis - Dana-Farber Cancer Institute
Publication Details: Annals of oncology, Vol.25, p.iv325
Identifiers: 991005969023802656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article